- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Metastatic Melanoma Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Metastatic Melanoma Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Metastatic Melanoma Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While AGI-134 segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Metastatic Melanoma Drug include Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., and NewLink Genetics Corporation, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Metastatic Melanoma Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
AGI-134
ALT-801
ALT-803
AMG-232
Others
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Metastatic Melanoma Drug market are listed below:
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Metastatic Melanoma Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Metastatic Melanoma Drug, with price, sales, revenue and global market share of Metastatic Melanoma Drug from 2019 to 2022.
Chapter 3, the Metastatic Melanoma Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Metastatic Melanoma Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Metastatic Melanoma Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Metastatic Melanoma Drug.
Chapter 13, 14, and 15, to describe Metastatic Melanoma Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Metastatic Melanoma Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Metastatic Melanoma Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 AGI-134
1.2.3 ALT-801
1.2.4 ALT-803
1.2.5 AMG-232
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Metastatic Melanoma Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Metastatic Melanoma Drug Market Size & Forecast
1.4.1 Global Metastatic Melanoma Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Metastatic Melanoma Drug Sales in Volume (2017-2028)
1.4.3 Global Metastatic Melanoma Drug Price (2017-2028)
1.5 Global Metastatic Melanoma Drug Production Capacity Analysis
1.5.1 Global Metastatic Melanoma Drug Total Production Capacity (2017-2028)
1.5.2 Global Metastatic Melanoma Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Metastatic Melanoma Drug Market Drivers
1.6.2 Metastatic Melanoma Drug Market Restraints
1.6.3 Metastatic Melanoma Drug Trends Analysis
2 Manufacturers Profiles
2.1 Merck & Co., Inc.
2.1.1 Merck & Co., Inc. Details
2.1.2 Merck & Co., Inc. Major Business
2.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Product and Services
2.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Merck KGaA
2.2.1 Merck KGaA Details
2.2.2 Merck KGaA Major Business
2.2.3 Merck KGaA Metastatic Melanoma Drug Product and Services
2.2.4 Merck KGaA Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Millennium Pharmaceuticals, Inc.
2.3.1 Millennium Pharmaceuticals, Inc. Details
2.3.2 Millennium Pharmaceuticals, Inc. Major Business
2.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product and Services
2.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Morphotek, Inc.
2.4.1 Morphotek, Inc. Details
2.4.2 Morphotek, Inc. Major Business
2.4.3 Morphotek, Inc. Metastatic Melanoma Drug Product and Services
2.4.4 Morphotek, Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 NewLink Genetics Corporation
2.5.1 NewLink Genetics Corporation Details
2.5.2 NewLink Genetics Corporation Major Business
2.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Product and Services
2.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Metastatic Melanoma Drug Product and Services
2.6.4 Novartis AG Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Omeros Corporation
2.7.1 Omeros Corporation Details
2.7.2 Omeros Corporation Major Business
2.7.3 Omeros Corporation Metastatic Melanoma Drug Product and Services
2.7.4 Omeros Corporation Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Oncolytics Biotech Inc.
2.8.1 Oncolytics Biotech Inc. Details
2.8.2 Oncolytics Biotech Inc. Major Business
2.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product and Services
2.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 OncoSec Medical Inc.
2.9.1 OncoSec Medical Inc. Details
2.9.2 OncoSec Medical Inc. Major Business
2.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Product and Services
2.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Ono Pharmaceutical Co., Ltd.
2.10.1 Ono Pharmaceutical Co., Ltd. Details
2.10.2 Ono Pharmaceutical Co., Ltd. Major Business
2.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product and Services
2.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Pfizer Inc.
2.11.1 Pfizer Inc. Details
2.11.2 Pfizer Inc. Major Business
2.11.3 Pfizer Inc. Metastatic Melanoma Drug Product and Services
2.11.4 Pfizer Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Pharmis Biofarmaceutica, Lda.
2.12.1 Pharmis Biofarmaceutica, Lda. Details
2.12.2 Pharmis Biofarmaceutica, Lda. Major Business
2.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product and Services
2.12.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Philogen S.p.A.
2.13.1 Philogen S.p.A. Details
2.13.2 Philogen S.p.A. Major Business
2.13.3 Philogen S.p.A. Metastatic Melanoma Drug Product and Services
2.13.4 Philogen S.p.A. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Plexxikon Inc.
2.14.1 Plexxikon Inc. Details
2.14.2 Plexxikon Inc. Major Business
2.14.3 Plexxikon Inc. Metastatic Melanoma Drug Product and Services
2.14.4 Plexxikon Inc. Metastatic Melanoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Metastatic Melanoma Drug Breakdown Data by Manufacturer
3.1 Global Metastatic Melanoma Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Metastatic Melanoma Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Metastatic Melanoma Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Metastatic Melanoma Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Metastatic Melanoma Drug Manufacturer Market Share in 2021
3.5 Global Metastatic Melanoma Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Metastatic Melanoma Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Metastatic Melanoma Drug Market Size by Region
4.1.1 Global Metastatic Melanoma Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Metastatic Melanoma Drug Revenue by Region (2017-2028)
4.2 North America Metastatic Melanoma Drug Revenue (2017-2028)
4.3 Europe Metastatic Melanoma Drug Revenue (2017-2028)
4.4 Asia-Pacific Metastatic Melanoma Drug Revenue (2017-2028)
4.5 South America Metastatic Melanoma Drug Revenue (2017-2028)
4.6 Middle East and Africa Metastatic Melanoma Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Metastatic Melanoma Drug Sales in Volume by Type (2017-2028)
5.2 Global Metastatic Melanoma Drug Revenue by Type (2017-2028)
5.3 Global Metastatic Melanoma Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Metastatic Melanoma Drug Sales in Volume by Application (2017-2028)
6.2 Global Metastatic Melanoma Drug Revenue by Application (2017-2028)
6.3 Global Metastatic Melanoma Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Metastatic Melanoma Drug Sales by Type (2017-2028)
7.2 North America Metastatic Melanoma Drug Sales by Application (2017-2028)
7.3 North America Metastatic Melanoma Drug Market Size by Country
7.3.1 North America Metastatic Melanoma Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Metastatic Melanoma Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Metastatic Melanoma Drug Sales by Type (2017-2028)
8.2 Europe Metastatic Melanoma Drug Sales by Application (2017-2028)
8.3 Europe Metastatic Melanoma Drug Market Size by Country
8.3.1 Europe Metastatic Melanoma Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Metastatic Melanoma Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Metastatic Melanoma Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Metastatic Melanoma Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Metastatic Melanoma Drug Market Size by Region
9.3.1 Asia-Pacific Metastatic Melanoma Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Metastatic Melanoma Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Metastatic Melanoma Drug Sales by Type (2017-2028)
10.2 South America Metastatic Melanoma Drug Sales by Application (2017-2028)
10.3 South America Metastatic Melanoma Drug Market Size by Country
10.3.1 South America Metastatic Melanoma Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Metastatic Melanoma Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Metastatic Melanoma Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Metastatic Melanoma Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Metastatic Melanoma Drug Market Size by Country
11.3.1 Middle East & Africa Metastatic Melanoma Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Metastatic Melanoma Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Metastatic Melanoma Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Metastatic Melanoma Drug
12.3 Metastatic Melanoma Drug Production Process
12.4 Metastatic Melanoma Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Metastatic Melanoma Drug Typical Distributors
13.3 Metastatic Melanoma Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Metastatic Melanoma Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Metastatic Melanoma Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Merck & Co., Inc. Major Business
Table 5. Merck & Co., Inc. Metastatic Melanoma Drug Product and Services
Table 6. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 8. Merck KGaA Major Business
Table 9. Merck KGaA Metastatic Melanoma Drug Product and Services
Table 10. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Millennium Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 12. Millennium Pharmaceuticals, Inc. Major Business
Table 13. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product and Services
Table 14. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Morphotek, Inc. Basic Information, Manufacturing Base and Competitors
Table 16. Morphotek, Inc. Major Business
Table 17. Morphotek, Inc. Metastatic Melanoma Drug Product and Services
Table 18. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. NewLink Genetics Corporation Basic Information, Manufacturing Base and Competitors
Table 20. NewLink Genetics Corporation Major Business
Table 21. NewLink Genetics Corporation Metastatic Melanoma Drug Product and Services
Table 22. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 24. Novartis AG Major Business
Table 25. Novartis AG Metastatic Melanoma Drug Product and Services
Table 26. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Omeros Corporation Basic Information, Manufacturing Base and Competitors
Table 28. Omeros Corporation Major Business
Table 29. Omeros Corporation Metastatic Melanoma Drug Product and Services
Table 30. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Oncolytics Biotech Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Oncolytics Biotech Inc. Major Business
Table 33. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product and Services
Table 34. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. OncoSec Medical Inc. Basic Information, Manufacturing Base and Competitors
Table 36. OncoSec Medical Inc. Major Business
Table 37. OncoSec Medical Inc. Metastatic Melanoma Drug Product and Services
Table 38. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Ono Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 40. Ono Pharmaceutical Co., Ltd. Major Business
Table 41. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product and Services
Table 42. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Pfizer Inc. Major Business
Table 45. Pfizer Inc. Metastatic Melanoma Drug Product and Services
Table 46. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Pharmis Biofarmaceutica, Lda. Basic Information, Manufacturing Base and Competitors
Table 48. Pharmis Biofarmaceutica, Lda. Major Business
Table 49. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product and Services
Table 50. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Philogen S.p.A. Basic Information, Manufacturing Base and Competitors
Table 52. Philogen S.p.A. Major Business
Table 53. Philogen S.p.A. Metastatic Melanoma Drug Product and Services
Table 54. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Plexxikon Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Plexxikon Inc. Major Business
Table 57. Plexxikon Inc. Metastatic Melanoma Drug Product and Services
Table 58. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Global Metastatic Melanoma Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
Table 60. Global Metastatic Melanoma Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 61. Market Position of Manufacturers in Metastatic Melanoma Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 62. Global Metastatic Melanoma Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 63. Head Office and Metastatic Melanoma Drug Production Site of Key Manufacturer
Table 64. Metastatic Melanoma Drug New Entrant and Capacity Expansion Plans
Table 65. Metastatic Melanoma Drug Mergers & Acquisitions in the Past Five Years
Table 66. Global Metastatic Melanoma Drug Sales by Region (2017-2022) & (K Pcs)
Table 67. Global Metastatic Melanoma Drug Sales by Region (2023-2028) & (K Pcs)
Table 68. Global Metastatic Melanoma Drug Revenue by Region (2017-2022) & (USD Million)
Table 69. Global Metastatic Melanoma Drug Revenue by Region (2023-2028) & (USD Million)
Table 70. Global Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 71. Global Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 72. Global Metastatic Melanoma Drug Revenue by Type (2017-2022) & (USD Million)
Table 73. Global Metastatic Melanoma Drug Revenue by Type (2023-2028) & (USD Million)
Table 74. Global Metastatic Melanoma Drug Price by Type (2017-2022) & (USD/Pcs)
Table 75. Global Metastatic Melanoma Drug Price by Type (2023-2028) & (USD/Pcs)
Table 76. Global Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 77. Global Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 78. Global Metastatic Melanoma Drug Revenue by Application (2017-2022) & (USD Million)
Table 79. Global Metastatic Melanoma Drug Revenue by Application (2023-2028) & (USD Million)
Table 80. Global Metastatic Melanoma Drug Price by Application (2017-2022) & (USD/Pcs)
Table 81. Global Metastatic Melanoma Drug Price by Application (2023-2028) & (USD/Pcs)
Table 82. North America Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 83. North America Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 84. North America Metastatic Melanoma Drug Revenue by Country (2017-2022) & (USD Million)
Table 85. North America Metastatic Melanoma Drug Revenue by Country (2023-2028) & (USD Million)
Table 86. North America Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 87. North America Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 88. North America Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 89. North America Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 90. Europe Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 91. Europe Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 92. Europe Metastatic Melanoma Drug Revenue by Country (2017-2022) & (USD Million)
Table 93. Europe Metastatic Melanoma Drug Revenue by Country (2023-2028) & (USD Million)
Table 94. Europe Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 95. Europe Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 96. Europe Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 97. Europe Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 98. Asia-Pacific Metastatic Melanoma Drug Sales by Region (2017-2022) & (K Pcs)
Table 99. Asia-Pacific Metastatic Melanoma Drug Sales by Region (2023-2028) & (K Pcs)
Table 100. Asia-Pacific Metastatic Melanoma Drug Revenue by Region (2017-2022) & (USD Million)
Table 101. Asia-Pacific Metastatic Melanoma Drug Revenue by Region (2023-2028) & (USD Million)
Table 102. Asia-Pacific Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 103. Asia-Pacific Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 104. Asia-Pacific Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 105. Asia-Pacific Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 106. South America Metastatic Melanoma Drug Sales by Country (2017-2022) & (K Pcs)
Table 107. South America Metastatic Melanoma Drug Sales by Country (2023-2028) & (K Pcs)
Table 108. South America Metastatic Melanoma Drug Revenue by Country (2017-2022) & (USD Million)
Table 109. South America Metastatic Melanoma Drug Revenue by Country (2023-2028) & (USD Million)
Table 110. South America Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 111. South America Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 112. South America Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 113. South America Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 114. Middle East & Africa Metastatic Melanoma Drug Sales by Region (2017-2022) & (K Pcs)
Table 115. Middle East & Africa Metastatic Melanoma Drug Sales by Region (2023-2028) & (K Pcs)
Table 116. Middle East & Africa Metastatic Melanoma Drug Revenue by Region (2017-2022) & (USD Million)
Table 117. Middle East & Africa Metastatic Melanoma Drug Revenue by Region (2023-2028) & (USD Million)
Table 118. Middle East & Africa Metastatic Melanoma Drug Sales by Type (2017-2022) & (K Pcs)
Table 119. Middle East & Africa Metastatic Melanoma Drug Sales by Type (2023-2028) & (K Pcs)
Table 120. Middle East & Africa Metastatic Melanoma Drug Sales by Application (2017-2022) & (K Pcs)
Table 121. Middle East & Africa Metastatic Melanoma Drug Sales by Application (2023-2028) & (K Pcs)
Table 122. Metastatic Melanoma Drug Raw Material
Table 123. Key Manufacturers of Metastatic Melanoma Drug Raw Materials
Table 124. Direct Channel Pros & Cons
Table 125. Indirect Channel Pros & Cons
Table 126. Metastatic Melanoma Drug Typical Distributors
Table 127. Metastatic Melanoma Drug Typical Customers
List of Figures
Figure 1. Metastatic Melanoma Drug Picture
Figure 2. Global Metastatic Melanoma Drug Revenue Market Share by Type in 2021
Figure 3. AGI-134
Figure 4. ALT-801
Figure 5. ALT-803
Figure 6. AMG-232
Figure 7. Others
Figure 8. Global Metastatic Melanoma Drug Revenue Market Share by Application in 2021
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Metastatic Melanoma Drug Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028
Figure 13. Global Metastatic Melanoma Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Metastatic Melanoma Drug Sales (2017-2028) & (K Pcs)
Figure 15. Global Metastatic Melanoma Drug Price (2017-2028) & (USD/Pcs)
Figure 16. Global Metastatic Melanoma Drug Production Capacity (2017-2028) & (K Pcs)
Figure 17. Global Metastatic Melanoma Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. Metastatic Melanoma Drug Market Drivers
Figure 19. Metastatic Melanoma Drug Market Restraints
Figure 20. Metastatic Melanoma Drug Market Trends
Figure 21. Global Metastatic Melanoma Drug Sales Market Share by Manufacturer in 2021
Figure 22. Global Metastatic Melanoma Drug Revenue Market Share by Manufacturer in 2021
Figure 23. Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 Metastatic Melanoma Drug Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 Metastatic Melanoma Drug Manufacturer (Revenue) Market Share in 2021
Figure 26. Global Metastatic Melanoma Drug Sales Market Share by Region (2017-2028)
Figure 27. Global Metastatic Melanoma Drug Revenue Market Share by Region (2017-2028)
Figure 28. North America Metastatic Melanoma Drug Revenue (2017-2028) & (USD Million)
Figure 29. Europe Metastatic Melanoma Drug Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific Metastatic Melanoma Drug Revenue (2017-2028) & (USD Million)
Figure 31. South America Metastatic Melanoma Drug Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa Metastatic Melanoma Drug Revenue (2017-2028) & (USD Million)
Figure 33. Global Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 34. Global Metastatic Melanoma Drug Revenue Market Share by Type (2017-2028)
Figure 35. Global Metastatic Melanoma Drug Price by Type (2017-2028) & (USD/Pcs)
Figure 36. Global Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 37. Global Metastatic Melanoma Drug Revenue Market Share by Application (2017-2028)
Figure 38. Global Metastatic Melanoma Drug Price by Application (2017-2028) & (USD/Pcs)
Figure 39. North America Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 40. North America Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 41. North America Metastatic Melanoma Drug Sales Market Share by Country (2017-2028)
Figure 42. North America Metastatic Melanoma Drug Revenue Market Share by Country (2017-2028)
Figure 43. United States Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 47. Europe Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 48. Europe Metastatic Melanoma Drug Sales Market Share by Country (2017-2028)
Figure 49. Europe Metastatic Melanoma Drug Revenue Market Share by Country (2017-2028)
Figure 50. Germany Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Metastatic Melanoma Drug Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Metastatic Melanoma Drug Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific Metastatic Melanoma Drug Revenue Market Share by Region (2017-2028)
Figure 59. China Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 66. South America Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 67. South America Metastatic Melanoma Drug Sales Market Share by Country (2017-2028)
Figure 68. South America Metastatic Melanoma Drug Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa Metastatic Melanoma Drug Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa Metastatic Melanoma Drug Revenue Market Share by Region (2017-2028)
Figure 75. Turkey Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa Metastatic Melanoma Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of Metastatic Melanoma Drug in 2021
Figure 80. Manufacturing Process Analysis of Metastatic Melanoma Drug
Figure 81. Metastatic Melanoma Drug Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
